摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Benzyl-N'-methyl-sulfonyldiamid | 26120-09-2

中文名称
——
中文别名
——
英文名称
N-Benzyl-N'-methyl-sulfonyldiamid
英文别名
N-Benzyl-N'-methylsulfamid;N-(methylsulfamoyl)-1-phenylmethanamine
N-Benzyl-N'-methyl-sulfonyldiamid化学式
CAS
26120-09-2
化学式
C8H12N2O2S
mdl
——
分子量
200.261
InChiKey
KEKCBMWGXJQRTR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    66.6
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    Diethyl-N-methyl-sulfonyl-dicarbamat 、 氯化苄 生成 N-Benzyl-N'-methyl-sulfonyldiamid
    参考文献:
    名称:
    Solvent cage effect in the photolysis of azomethane in aqueous alcohols and other media: a semiempirical correlation with macroscopic solvent parameters
    摘要:
    DOI:
    10.1021/ja00437a031
点击查看最新优质反应信息

文献信息

  • [EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2010036632A1
    公开(公告)日:2010-04-01
    Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    公开的是化合物的公式(I),用于治疗通过CCR1活性介导或维持的多种疾病和疾病,包括自身免疫性疾病,如风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。
  • [EN] INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS INDAZOLE COMME ANTAGONISTES DES RÉCEPTEURS CCR1
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009134666A1
    公开(公告)日:2009-11-05
    Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    揭示了吲唑烯化合物,其作为CCR1活性拮抗剂是有用的,因此可用于治疗通过CCR1活性介导或维持的多种疾病和疾病,包括自身免疫疾病,如类风湿性关节炎和多发性硬化症。还披露了包含这些化合物的药物组合物,使用这些化合物治疗各种疾病和疾病的方法,制备这些化合物的过程以及在这些过程中有用的中间体。
  • Anti-Infective Agents
    申请人:Hutchinson Douglas K.
    公开号:US20080193413A1
    公开(公告)日:2008-08-14
    Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
    具有公式的化合物是丙型肝炎(HCV)聚合酶抑制剂。还公开了一种用于抑制丙型肝炎(HCV)聚合酶的组合物和方法,制备化合物的过程以及用于该过程的合成中间体。
  • Indazole Compounds As CCR1 Receptor Antagonists
    申请人:KUZMICH Daniel
    公开号:US20110294808A1
    公开(公告)日:2011-12-01
    Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    公开了一种吲唑化合物,可用作CCR1活性的拮抗剂,因此可用于治疗通过CCR1活性介导或维持的各种疾病和障碍,包括自身免疫性疾病,如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物,使用这些化合物治疗各种疾病和障碍的方法,制备这些化合物的过程以及在这些过程中有用的中间体。
  • Cycloalkyl inhibitors of potassium channel function
    申请人:Bristol-Myers Squibb Company
    公开号:EP2253328A1
    公开(公告)日:2010-11-24
    Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kvl subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
    可用作钾通道功能抑制剂的新型环烷基化合物(特别是电压门控 K+ 通道 Kvl 亚家族的抑制剂,尤其是与超快速活化延迟整流 K+ 电流 IKur 有关的 Kv1.5 抑制剂)、使用此类化合物预防和治疗心律失常及 IKur 相关疾病的方法,以及含有此类化合物的药物组合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐